Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

RNA-Binding Proteins in Female Reproductive Pathologies.

Khalaj K, Miller JE, Fenn CR, Ahn S, Luna RL, Symons L, Monsanto SP, Koti M, Tayade C.

Am J Pathol. 2017 Apr 10. pii: S0002-9440(17)30076-7. doi: 10.1016/j.ajpath.2017.01.017. [Epub ahead of print] Review.

PMID:
28408123
2.

CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.

K Au K, Peterson N, Truesdell P, Reid-Schachter G, Khalaj K, Ren R, Francis JA, H Graham C, W Craig A, Koti M.

Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208-1. doi: 10.1016/j.ygyno.2017.03.007. [Epub ahead of print]

PMID:
28318643
3.

Extracellular vesicle mediated intercellular communication at the porcine maternal-fetal interface: A new paradigm for conceptus-endometrial cross-talk.

Bidarimath M, Khalaj K, Kridli RT, Kan FW, Koti M, Tayade C.

Sci Rep. 2017 Jan 12;7:40476. doi: 10.1038/srep40476.

4.

STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.

Au KK, Le Page C, Ren R, Meunier L, Clément I, Tyrishkin K, Peterson N, Kendall-Dupont J, Childs T, Francis JA, Graham CH, Craig AW, Squire JA, Mes-Masson AM, Koti M.

J Pathol Clin Res. 2016 Sep 19;2(4):259-270. eCollection 2016 Oct.

5.

Implications of immune dysfunction on endometriosis associated infertility.

Miller JE, Ahn SH, Monsanto SP, Khalaj K, Koti M, Tayade C.

Oncotarget. 2017 Jan 24;8(4):7138-7147. doi: 10.18632/oncotarget.12577. Review.

6.

Altered expression of chemokines and their receptors at porcine maternal-fetal interface during early and mid-gestational fetal loss.

Bidarimath M, Khalaj K, Kridli RT, Wessels JM, Koti M, Tayade C.

Cell Tissue Res. 2016 Dec;366(3):747-761. Epub 2016 Aug 8.

PMID:
27503377
7.

Immune-inflammation gene signatures in endometriosis patients.

Ahn SH, Khalaj K, Young SL, Lessey BA, Koti M, Tayade C.

Fertil Steril. 2016 Nov;106(6):1420-1431.e7. doi: 10.1016/j.fertnstert.2016.07.005. Epub 2016 Jul 27.

PMID:
27475412
8.

A primer on tumour immunology and prostate cancer immunotherapy.

Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, Drachenberg DE, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):60-5. doi: 10.5489/cuaj.3418. Review. No abstract available.

9.

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.

Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AW, Graham CH.

Oncotarget. 2016 Mar 1;7(9):10557-67. doi: 10.18632/oncotarget.7235.

10.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.459. No abstract available.

11.

Current state of biomarkers in ovarian cancer prognosis.

Au KK, Josahkian JA, Francis JA, Squire JA, Koti M.

Future Oncol. 2015;11(23):3187-95. doi: 10.2217/fon.15.251. Epub 2015 Nov 9. Review.

PMID:
26551891
12.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].

13.

Mechanisms of hypoxia-mediated immune escape in cancer.

Barsoum IB, Koti M, Siemens DR, Graham CH.

Cancer Res. 2014 Dec 15;74(24):7185-90. doi: 10.1158/0008-5472.CAN-14-2598. Epub 2014 Oct 24.

14.

Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.

Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M.

PLoS One. 2014 May 16;9(5):e95843. doi: 10.1371/journal.pone.0095843. eCollection 2014.

15.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

16.

Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems.

Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K.

Bioinformatics. 2014 Mar 1;30(5):712-8. doi: 10.1093/bioinformatics/btt602. Epub 2013 Oct 21.

PMID:
24149051
17.

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H.

BMC Cancer. 2012 Mar 19;12:91. doi: 10.1186/1471-2407-12-91.

18.

Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.

Weberpals JI, Koti M, Squire JA.

Cancer Genet. 2011 Oct;204(10):525-35. doi: 10.1016/j.cancergen.2011.09.004. Review.

PMID:
22137482
19.

A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1.

Koti M, Nagy E, Kaushik AK.

Vaccine. 2011 Oct 19;29(45):7905-12. doi: 10.1016/j.vaccine.2011.08.077. Epub 2011 Aug 26.

PMID:
21872632
20.

Novel atypical nucleotide insertions specifically at VH-DH junction generate exceptionally long CDR3H in cattle antibodies.

Koti M, Kataeva G, Kaushik AK.

Mol Immunol. 2010 Jul;47(11-12):2119-28. doi: 10.1016/j.molimm.2010.02.014.

PMID:
20435350

Supplemental Content

Support Center